Venture Capital

As Aqua Metals reports its 2025 financials, investors seek proof its recycling tech can deliver amid market volatility and new strategic partnerships.

Digital fabrication giant xTool is sponsoring Austin's Handbuilt Show, bridging the gap between laser precision and old-school motorcycle artistry.

A new challenger enters the ring. The Xtra Atto packs 4K power and a large sensor for $299, but can it truly compete with the giants of the POV camera world?

As elephant Tina faces a life-threatening illness, Samuel L. Jackson pressures the Tulsa Zoo for her and Billy's release to a sanctuary.

Navigator Medicines pushes two novel bispecific antibodies for Hidradenitis Suppurativa, promising better efficacy and patient-friendly dosing.

A federal court sided with Vitti Labs, ruling the FDA's interpretation of tissue rules "plainly erroneous." The decision could reshape the entire industry.

Independent firm FPA is nominated for a top Morningstar award alongside PIMCO and Vanguard, highlighting its rare focus on investor returns over asset size.

Despite citizenship law debates, investor demand for Portugal's Golden Visa remains strong, signaling a strategic shift towards long-term residency.

As co-founder Jürgen Bickel steps down, 14-year veteran David Männer takes the helm to navigate Storz & Bickel's future and drive Canopy's U.S. plans.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.

With a fresh Nasdaq listing and $57.2M in funding, Satellos is advancing a novel muscle-regenerating drug for Duchenne into pivotal pediatric trials.

Kontrol Technologies targets Ontario's aging apartments with a strategic HVAC buyout, but its cautious M&A history reveals a complex path forward.

The company aims to slash production costs by 50% with AI, while deploying a powerful open-source agent that brings both promise and significant risk.

Biocon names 30-year veteran Shreehas Tambe as its new CEO, consolidating its biosimilar and generics arms to create a global biopharma powerhouse.

The pharma giant's acquisition of Excellergy and its first-in-class Exl-111 could revolutionize treatment for millions with severe, debilitating allergies.

Agenus prepares a crucial update on its BOT+BAL immunotherapy, a potential breakthrough for cancers resistant to current treatments. What will they reveal?

OPAL Fuels' Co-CEO will keynote at ACT Expo, highlighting how renewable natural gas offers fleets a path to cost savings and deep decarbonization.

At a key investor conference, Renibus is pitching its two Phase 3 drugs, including one with a strategic pivot after a challenging trial result.

With $12M in new funding, a Houston startup is deploying its NASA-derived HVAC retrofit that promises to slash building energy bills by over 50%.

A new report slams the FDA for blocking vital treatments with rising costs and denials, but the agency faces a complex reality of reform and internal pressure.